MannKind traded at $3.80 this Wednesday June 29th, increasing $0.01 or 0.26 percent since the previous trading session. Looking back, over the last four weeks, MannKind gained 9.09 percent. Over the last 12 months, its price fell by 30.28 percent. Looking ahead, we forecast MannKind to be priced at 3.78 by the end of this quarter and at 3.48 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Adma Biologics 1.96 -0.06 -2.97% 22.50%
BioCryst Pharmaceuticals 10.81 0.35 3.35% -31.63%
ChemoCentryx 25.49 0.41 1.63% 90.37%
Dynavax Technologies 12.79 0.62 5.09% 29.85%
Halozyme Therapeutics 45.28 -0.50 -1.09% -0.29%
Immunogen 4.36 0.07 1.63% -33.84%
Insmed 20.07 0.16 0.80% -29.48%
Jazz Pharmaceuticals 156.36 1.12 0.72% -11.98%
Karyopharm Therapeutics 4.51 -0.07 -1.53% -56.30%
Eli Lilly 323.00 5.38 1.69% 40.73%
MacroGenics 3.02 0.01 0.33% -88.76%
MannKind 3.80 0.01 0.26% -30.28%
Merck & Co 92.51 0.62 0.67% 18.95%
Minerva Neurosciences 3.42 -0.02 -0.58% 47.41%
Novavax 51.85 0.79 1.55% -75.58%
Novo Nordisk A Fs 110.08 1.78 1.64% 31.41%
Pfizer 50.94 0.28 0.55% 30.08%
Peregrine Pharmaceuticals 15.17 -0.37 -2.38% -40.86%
Sanofi 100.88 1.51 1.52% 14.17%
Xencor 27.20 0.14 0.52% -21.14%

Indexes Price Day Year
USND 11178 -3.65 -0.03% -22.93%
US2000 1719 -19.47 -1.12% -25.59%

MannKind
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.